Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
8.26
USD
|
+8.12%
|
|
+6.03%
|
+34.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
204.6
|
499.2
|
193
|
105.1
|
123.9
|
312.7
|
-
|
-
|
Enterprise Value (EV)
1 |
123.8
|
345.2
|
73.88
|
-108.7
|
123.9
|
162.8
|
245.3
|
312.7
|
P/E ratio
|
-1.53
x
|
-4.46
x
|
-2.57
x
|
-0.53
x
|
-1.27
x
|
-3.06
x
|
-3.11
x
|
-3.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
14.2
x
|
13
x
|
-
|
95.9
x
|
82.2
x
|
167
x
|
EV / Revenue
|
-
|
-
|
5.42
x
|
-13.4
x
|
-
|
49.9
x
|
64.5
x
|
167
x
|
EV / EBITDA
|
-1.06
x
|
-4.09
x
|
-
|
-
|
-
|
-1.64
x
|
-2.4
x
|
-2.92
x
|
EV / FCF
|
-1.27
x
|
-6
x
|
-0.93
x
|
1.08
x
|
-
|
-2.14
x
|
-
|
-
|
FCF Yield
|
-78.4%
|
-16.7%
|
-107%
|
92.9%
|
-
|
-46.7%
|
-
|
-
|
Price to Book
|
2.24
x
|
2.98
x
|
0.9
x
|
0.22
x
|
-
|
1.5
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,066
|
4,390
|
7,353
|
19,528
|
20,177
|
37,861
|
-
|
-
|
Reference price
2 |
66.75
|
113.7
|
26.25
|
5.380
|
6.140
|
8.260
|
8.260
|
8.260
|
Announcement Date
|
3/12/20
|
3/15/21
|
3/14/22
|
3/23/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
13.62
|
8.094
|
-
|
3.262
|
3.803
|
1.874
|
EBITDA
1 |
-116.5
|
-84.48
|
-
|
-
|
-
|
-99.31
|
-102.1
|
-107.2
|
EBIT
1 |
-119.3
|
-88.41
|
-72.25
|
-99.27
|
-104.3
|
-111.8
|
-133.4
|
-143.5
|
Operating Margin
|
-
|
-
|
-530.5%
|
-1,226.51%
|
-
|
-3,427.82%
|
-3,507.29%
|
-7,656.66%
|
Earnings before Tax (EBT)
1 |
-117.2
|
-88.29
|
-72.19
|
-85.98
|
-96.02
|
-102.5
|
-125.7
|
-135.9
|
Net income
1 |
-117.2
|
-88.29
|
-72.19
|
-85.98
|
-96.02
|
-100.7
|
-121.1
|
-135.9
|
Net margin
|
-
|
-
|
-530.01%
|
-1,062.28%
|
-
|
-3,087.1%
|
-3,184.67%
|
-7,249.55%
|
EPS
2 |
-43.65
|
-25.50
|
-10.20
|
-10.10
|
-4.830
|
-2.703
|
-2.653
|
-2.279
|
Free Cash Flow
1 |
-97.1
|
-57.5
|
-79.04
|
-101
|
-
|
-76
|
-
|
-
|
FCF margin
|
-
|
-
|
-580.36%
|
-1,247.74%
|
-
|
-2,329.62%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/15/21
|
3/14/22
|
3/23/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.154
|
1.925
|
6.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.9041
|
0.9041
|
0.9041
|
0.4462
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-25.25
|
-23.99
|
-24.26
|
-24.53
|
-25.09
|
-
|
EBIT
1 |
-18.65
|
-25.37
|
-25.38
|
-21.13
|
-28.91
|
-32.03
|
-26.84
|
-23.11
|
-22.26
|
-26.86
|
-27.07
|
-28.48
|
-29.6
|
-29.63
|
-33.38
|
Operating Margin
|
-591.38%
|
-1,318.03%
|
-409.39%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,994.04%
|
-3,149.88%
|
-3,274.27%
|
-6,640.28%
|
-
|
Earnings before Tax (EBT)
1 |
-18.61
|
-25.33
|
-25.09
|
-20.41
|
-15.15
|
-30.07
|
-24.63
|
-20.98
|
-20.34
|
-24.3
|
-24.7
|
-26.12
|
-27.47
|
-26.78
|
-31.38
|
Net income
1 |
-18.61
|
-25.33
|
-25.1
|
-20.41
|
-15.15
|
-30.07
|
-24.63
|
-21
|
-20.34
|
-24.3
|
-24.7
|
-26.12
|
-27.47
|
-26.78
|
-31.38
|
Net margin
|
-590.04%
|
-1,315.74%
|
-404.84%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,731.7%
|
-2,888.82%
|
-3,038.14%
|
-6,002.63%
|
-
|
EPS
2 |
-2.550
|
-3.300
|
-3.300
|
-2.710
|
-0.6800
|
-1.540
|
-1.250
|
-1.050
|
-1.000
|
-0.6400
|
-0.6357
|
-0.6654
|
-0.6599
|
-0.6684
|
-0.7000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/22
|
4/27/22
|
8/11/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/14/23
|
11/8/23
|
3/13/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
80.9
|
154
|
119
|
214
|
-
|
150
|
67.4
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-97.1
|
-57.5
|
-79
|
-101
|
-
|
-76
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-114%
|
-83.2%
|
-42.4%
|
-41%
|
-
|
-60%
|
-79.8%
|
-80.6%
|
ROA (Net income/ Total Assets)
|
-96.5%
|
-64.3%
|
-35.8%
|
-34.9%
|
-
|
-48.6%
|
-
|
-
|
Assets
1 |
121.5
|
137.3
|
201.8
|
246.3
|
-
|
207.3
|
-
|
-
|
Book Value Per Share
2 |
29.80
|
38.10
|
29.30
|
24.90
|
-
|
5.520
|
-
|
-
|
Cash Flow per Share
|
-
|
-16.30
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.39
|
0.9
|
1.28
|
3.02
|
-
|
1.21
|
0.43
|
-
|
Capex / Sales
|
-
|
-
|
9.41%
|
37.25%
|
-
|
37.18%
|
11.2%
|
-
|
Announcement Date
|
3/12/20
|
3/15/21
|
3/14/22
|
3/23/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
8.26
USD Average target price
17.44
USD Spread / Average Target +111.19% Consensus |
1st Jan change
|
Capi.
|
---|
| +34.53% | 313M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|